Revolution Medicines, Inc.

RVMD · Healthcare · Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers

Revolution Medicines, Inc. (RVMD), in the Healthcare sector, has 51 disclosed filings on Paydirt over the trailing twelve months from 10 corporate insiders: 0 purchases and 51 sales, 1 filed past the deadline. Filers took a median of 2 days from execution to disclosure, and the most recent trade was executed Sep 16 and filed Sep 18. The most active filer was Mark A Goldsmith with 19 filings.

Add to watchlist

Filings, ttm

0 buys · 51 sells · 1 late

Traders, ttm

10 insiders

Volume, ttmiDollar value disclosed in the window

$151.3M

estimated for Congress, as filed for insiders

Median delay

execution to disclosure

Last traded

Sep 16

Filed Sep 18

ADViAverage daily dollar volume

$548.2M

market data

Share price · 12M

$210 (+372.9%)

Adjusted for splits and dividends.

Volume by month

Buys $60.0M Sells $172.9M

Estimated for Congress, as filed for insiders · by filing month · past 24 months

Who filed

Mark A Goldsmith See Remarks 19 filings SK

Stephen Michael Kelsey See Remarks 13 filings JA

Jack Anders Chief Financial Officer 12 filings JC

Jeff Cislini SVP & General Counsel 11 filings MH

Margaret A Horn Chief Operating Officer 11 filings AM

Anthony Mancini See Remarks 6 filings LK

Lorence H. Kim Director 2 filings SP

Sushil Patel Director 2 filings

Recent filings

Anthony ManciniSALE See Remarks $348K
1,747 sh × $199.30
Exec Sep 16
Filed Sep 18 · 6:05 PM ET Stephen Michael KelseySALE See Remarks $1.1M
5,484 sh × $199.30
Exec Sep 16
Filed Sep 18 · 6:04 PM ET Margaret A HornSALE Chief Operating Officer $975K
4,891 sh × $199.30
Exec Sep 16
Filed Sep 18 · 6:03 PM ET Mark A GoldsmithSALE See Remarks $2.7M
13,775 sh × $199.30
Exec Sep 16
Filed Sep 18 · 6:02 PM ET Jeff CisliniSALE SVP & General Counsel $660K
3,314 sh × $199.30
Exec Sep 16
Filed Sep 18 · 6:01 PM ET Jack AndersSALE Chief Financial Officer $796K
3,992 sh × $199.30
Exec Sep 16
Filed Sep 18 · 6:00 PM ET Stephen Michael KelseySALE See Remarks $18.7M
92,531 sh across 8 lots
Exec Sep 11
Filed Sep 15 · 6:00 PM ET Anthony ManciniSALE See Remarks $3.1M
15,148 sh across 4 lots
Exec Sep 10
Filed Sep 14 · 6:03 PM ET Lorence H. KimSALE Director $3.5M
16,719 sh across 6 lots
Exec Sep 8
Filed Sep 10 · 5:52 PM ET Lorence H. KimSALE Director $11.3M
55,700 sh across 6 lots
Exec Aug 31
Filed Sep 2 · 4:30 PM ET Jeff CisliniSALE General Counsel $11.9M
56,894 sh across 6 lots
Exec Aug 21
Filed Aug 25 · 4:06 PM ET Mark A GoldsmithSALE See Remarks $17.7M
84,644 sh across 10 lots
Exec Aug 21
Filed Aug 25 · 4:06 PM ET Sushil PatelSALE Director $919K
4,880 sh across 6 lots
Exec Jun 29
Filed Jul 1 · 6:25 PM ET Jack AndersSALE Chief Financial Officer $3.3M
19,700 sh across 3 lots
Exec Jun 24
Filed Jun 26 · 5:30 PM ET Stephen Michael KelseySALE See Remarks $652K
4,175 sh × $156.12
Exec Jun 16
Filed Jun 18 · 5:30 PM ET Jack AndersSALE Chief Financial Officer $425K
2,722 sh × $156.12
Exec Jun 16
Filed Jun 18 · 5:30 PM ET Jeff CisliniSALE General Counsel $337K
2,157 sh × $156.12
Exec Jun 16
Filed Jun 18 · 5:30 PM ET Mark A GoldsmithSALE See Remarks $1.6M
10,020 sh × $156.12
Exec Jun 16
Filed Jun 18 · 5:30 PM ET Anthony ManciniSALE See Remarks $720K
4,615 sh × $156.12
Exec Jun 16
Filed Jun 18 · 5:30 PM ET Margaret A HornSALE Chief Operating Officer $15.0M
93,575 sh across 3 lots
Exec Jun 16 2025
Filed Jun 17 · 5:30 PM ET † Margaret A HornSALE Chief Operating Officer $1.4M
9,300 sh across 5 lots
Exec Jun 11
Filed Jun 15 · 5:30 PM ET Anthony ManciniSALE See Remarks $415K
2,700 sh across 2 lots
Exec May 26
Filed May 28 · 5:30 PM ET Anthony ManciniSALE See Remarks $359K
2,720 sh across 2 lots
Exec Apr 27
Filed Apr 29 · 5:30 PM ET Mark A GoldsmithSALE See Remarks $18.0M
120,000 sh × $150.09
Exec Apr 15
Filed Apr 17 · 5:30 PM ET Anthony ManciniSALE See Remarks $3.5M
37,050 sh across 4 lots
Exec Mar 25
Filed Mar 26 · 5:30 PM ET